SCHEMBL6315826

SCHEMBL6315826

CC(=O)Nc1ccc(C(=O)NCC2Cc3c(sc(NC(=O)C(=O)O)c3C(=O)O)CO2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB7A P51149 4/20 0.46
PTPN1 P18031 7/20 0.42
PTPRC P08575 2/20 0.42
PTPN2 P17706 2/20 0.42
PTPRB P23467 2/20 0.42
PTPRE P23469 2/20 0.42
LMNA P02545 2/20 0.42
ALDH1A1 P00352 4/20 0.41
KMT2A Q03164 3/20 0.41
MAPT P10636 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 2/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
HPGD P15428 4/20 0.41
TSHR P16473 1/20 0.41
PTPN6 P29350 1/20 0.40
NOD2 Q9HC29 1/20 0.40
TNF P01375 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6206528 0.89 RAB7A (0.55) RAB7APTPN1PTPRCPTPN2PTPRB
SCHEMBL6317331 0.88 SMN1; SMN2 (0.45) RAB7APTPN1PTPRCPTPN2PTPRB
SCHEMBL6315982 0.88 SMN1; SMN2 (0.49) RAB7APTPN1PTPRCPTPN2PTPRB
SCHEMBL6315632 0.85 RAB7A (0.47) RAB7APTPN1PTPRCPTPN2PTPRB
SCHEMBL6316713 0.84 RAB7A (0.45) RAB7APTPN1PTPRCPTPN2PTPRB
SCHEMBL6315228 0.84 PTPN1 (0.43) RAB7APTPN1PTPRCPTPN2PTPRB
SCHEMBL6316963 0.83 PTPN1 (0.47) RAB7APTPN1PTPRCPTPN2PTPRB
SCHEMBL6315022 0.83 RAB7A (0.51) RAB7APTPN1PTPRCPTPN2PTPRB
SCHEMBL6315979 0.82 MEN1 (0.54) RAB7APTPN1LMNAALDH1A1KMT2A
SCHEMBL6205718 0.82 KMT2A (0.49) RAB7APTPN1PTPRCPTPN2PTPRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6410586-B1 ANTICOAGULANTS; INSULIN RESISTANCE; ANTIALLERGENS NOVO NORDISK A/S (DK) 2002-06-25 US claimed
EP-1080095-A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) NOVO NORDISK A/S (DK) 2001-03-07 EP claimed
WO-1999046267-A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) NOVO NORDISK A/S (DK) 1999-09-16 WO claimed
US-6951878-B2 Benzo[b]thiophenyl or tetrahydro-benzo[b]thiophenyl modulators of protein tyrosine phosphatases (PTPases) NOVO NORDISK A/S (DK) 2005-10-04 US disclosed
US-20030069267-A1 Modulators of protein tyrosine phosphatases (PTPases) MOLLER NIELS PETER HUNDAHL (DK) 2003-04-10 US disclosed
US-6410586-B1 ANTICOAGULANTS; INSULIN RESISTANCE; ANTIALLERGENS NOVO NORDISK A/S (DK) 2002-06-25 US disclosed
US-6262044-B1 CONTAINING AN AMIDE-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE RING NOVO NORDISK A/S (DK) 2001-07-17 US disclosed
EP-1080095-A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) NOVO NORDISK A/S (DK) 2001-03-07 EP disclosed
WO-1999046267-A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) NOVO NORDISK A/S (DK) 1999-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069267-A1 Modulators of protein tyrosine phosphatases (PTPases) PTPRCAP, PTPRS, PTPRA RAB7A 3644/4885PTPN1 7/4885PTPRC 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.